October 30, 2019 / 2:08 PM / a month ago

Merck loses bid to revive $2.54 billion patent verdict against Gilead

Oct 30 (Reuters) - A U.S. appeals court on Wednesday dealt a major blow to Merck & Co Inc as it upheld a ruling that threw out a $2.54 billion jury verdict the drugmaker had won against Gilead Sciences Inc.

A three-judge panel of the U.S. Court of Appeals for the Federal Circuit upheld a Delaware judge’s determination that the Merck patent at issue in the case, which relates to hepatitis C treatment, should not have been granted.

Reporting by Jan Wolfe; Editing by Susan Fenton

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below